Overview of Acon

Property	Description
Active ingredient	Aceclofenac
Form	Oral Tablet
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Relief of pain, inflammation, and fever
Origin	Synthetic chemical compound

What Type of Medicine is Acon?

Acon is a prescription medication whose active ingredient is Aceclofenac, and it belongs to the major drug class known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This classification means its primary function is to relieve symptoms caused by inflammation and pain by inhibiting the production of certain body chemicals.

Aceclofenac is a synthetic chemical compound created in a laboratory, not derived directly from a natural source. Its identity as an NSAID means it is specifically positioned for conditions where both pain and swelling are present, such as managing short-term musculoskeletal discomfort. Aceclofenac is chemically related to diclofenac but is recognized in clinical practice for its distinct metabolic profile.

How is Acon Composed and Taken?

Acon is composed as an oral tablet for administration by mouth, and it is classified as a single-ingredient medicine. The therapeutic effect comes entirely from the active ingredient, Aceclofenac, without combining it with other active compounds. Pharmacological evidence indicates that Aceclofenac demonstrates a high bioavailability when administered orally, ensuring efficient absorption.

The oral route provides systemic relief, meaning the active substance is absorbed into the bloodstream to target internal or widespread pain and inflammation. The typical formulation is often designed as a film-coated tablet to ensure stability and ease of swallowing.

What is Acon's General Purpose?

The general purpose of Acon is to act as a potent analgesic (pain reliever) and anti-inflammatory agent to reduce discomfort and swelling. It achieves this by targeting the body’s specific response systems that trigger pain, swelling, and fever, effectively helping to manage these three core symptoms.

This powerful triple-action benefit of relieving pain, reducing swelling, and bringing down a fever makes it a valuable tool for symptomatic management where the inflammatory response is causing distress. This capability to simultaneously address multiple symptoms is a hallmark of the NSAID class to which Aceclofenac belongs.

What side effects are possible with Acon?

Possible side effects and safety information

This section outlines the officially documented adverse effects and safety characteristics of Acon (Aceclofenac), based strictly on governmental regulatory prescribing information. Adverse reactions are grouped by frequency and the body system affected.

Official Adverse Reactions and Frequency

Side effects are categorized by frequency, ranging from Common (ge 1/100 to < 1/10) to Very Rare (< 1/10,000). The most commonly affected organ systems are the Gastrointestinal and Hepatobiliary systems.

System-Organ Class	Common Adverse Reactions
Gastrointestinal disorders	Dyspepsia, Abdominal pain, Nausea, Diarrhea
Hepatobiliary disorders	Hepatic enzymes increased
Nervous System disorders	Dizziness

Uncommon reactions may include flatulence, gastritis, rash, and pruritus. Rare reactions include gastrointestinal bleeding and anaphylactic reactions, which require immediate medical attention.

Serious Safety Considerations

The medicine is associated with a risk of Serious Adverse Reactions, which are documented in official labeling. These include potentially fatal events such as Gastrointestinal Bleeding, Ulceration, or Perforation, and severe skin reactions like Stevens-Johnson syndrome (SJS). Use may also carry a small risk of serious Cardiovascular events, including Myocardial Infarction (heart attack) and Stroke.

Population-Specific Safety Notes

Safety constraints apply to specific populations. The medicine is contraindicated during the third trimester of pregnancy. The Elderly are documented as having an increased frequency of adverse reactions, particularly serious gastrointestinal issues. Furthermore, the medicine is contraindicated in patients with established Ischaemic Heart Disease or severe renal or hepatic failure. Cardiovascular risks may increase with the dose and duration of exposure, necessitating the use of the lowest effective dose for the shortest possible duration.

Overdose and Emergency Response

The official regulatory documentation for Acon (Aceclofenac) overdose indicates that many cases are asymptomatic or present with mild, self-limiting manifestations such as nausea, vomiting, epigastric pain, headache, or drowsiness. However, serious overdose carries the documented potential for severe outcomes, including life-threatening complications like acute renal failure, gastrointestinal bleeding, seizures, and metabolic acidosis.

Due to the systemic risks, seeking immediate medical attention is required for any suspected overdose, even if early symptoms are absent. Emergency services must be contacted immediately if severe signs, such as convulsions or loss of consciousness, are present. Management is recognized by regulatory authorities as primarily symptomatic and supportive treatment, as no specific antidote is known.

Documented procedures may include the administration of activated charcoal and mandatory hospital monitoring of vital signs and organ function (e.g., renal and hepatic). Regulatory information also notes that the elderly and individuals with pre-existing renal, hepatic, or cardiac impairment are at increased risk for serious adverse effects following an overdose.

Therapeutic Uses of Acon

What Acon Treats: Main Uses and Benefits

Acon (Aceclofenac) plays a role in managing the overall symptom burden associated with symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity. The medication is commonly used across domains where additional symptomatic support is needed, primarily in musculoskeletal and inflammatory contexts.

It is considered relevant for conditions characterized by symptoms that become more disruptive during flare-ups, including Rheumatoid Arthritis, Osteoarthritis, and Ankylosing Spondylitis. It is also applied in clinical settings where short-term symptomatic assistance is appropriate, such as managing pain from acute injuries like lumbago and tendinitis, and the episodic discomfort of primary dysmenorrhea. The use of this medicine contributes to improved comfort during periods of heightened symptoms.

“The medication is relevant in scenarios where additional management of discomfort is sought, often during phases when symptoms become more noticeable.”

Quick Fact: Relief for Pain and Inflammation

Acon may assist with managing symptom clusters that are intense or disruptive, specifically when the patient experiences the combination of pain, swelling, and an associated fever.

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Acon

Regulatory agencies define the approved population for Acon (Aceclofenac) through strict contraindications and conditional use requirements. The medicine is primarily indicated and approved for use in adult populations.

Classification	Rule or Status (As Stated in Regulatory Documents)
Absolute Contraindication	Severe hepatic failure, severe renal failure, active GI ulcer/hemorrhage, severe heart failure (NYHA Class II-IV), established arterial disease, and the last trimester of pregnancy.
Hypersensitivity Ban	History of allergic reactions (asthma, rhinitis, urticaria) to aspirin or other NSAIDs.
Pediatric Use	Not recommended for children and adolescents (under 18 years) as safety and efficacy have not been established through clinical data.
Conditional Use	Patients with mild to moderate hepatic or renal impairment must be treated under close medical surveillance. Elderly patients require caution and the lowest effective dose due to increased risk of serious adverse reactions.
Reproductive Status	Contraindicated in the last trimester of pregnancy and not recommended for breastfeeding mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Acon’s interaction profile details required restrictions and potential outcomes when co-administered with other substances, based on official regulatory documentation. Co-administration with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin and COX-2 selective inhibitors, is officially avoided due to the increased risk of gastrointestinal adverse effects.

Exposure Modification

The medicine may cause exposure modification of certain concomitant agents. It is documented to inhibit the renal clearance of Lithium, leading to increased serum concentrations of Lithium. It also decreases the elimination of Methotrexate, which may result in increased plasma levels. Co-administration with Cardiac Glycosides may similarly increase their plasma levels.

Pharmacodynamic Effects and Restrictions

Pharmacodynamic interactions primarily involve a reinforced bleeding risk when taken with Anticoagulants like Warfarin, Corticosteroids, or SSRIs. Furthermore, the medicine is officially noted to reduce the efficacy of Antihypertensives (ACE Inhibitors and ARBs) and Diuretics. This combination also carries an increased risk of nephrotoxicity, which is officially stated to be higher in elderly or dehydrated patients. A timing restriction mandates that Acon must not be used for 8–12 days after Mifepristone administration to prevent reduced efficacy.

Mechanism of Action

Molecular Mechanism: Preferential COX-2 Inhibition

The core mechanism involves the active ingredient acting as a competitive inhibitor of the Cyclooxygenase (COX) enzymes, particularly the COX-2 isoform. By preferentially blocking COX-2, the drug limits the production of inflammatory mediators, such as Prostaglandin E2 ( PGE2), through the Arachidonic Acid Cascade . This molecular action directly modifies the activity within the inflammatory signaling cascade.

Physiological Cascade: Nociceptor Modulation and Thermoregulation

The reduction in PGE2 triggers a physiological cascade: a decrease in local PGE2 modulates the sensitization of peripheral nociceptors (sensory nerve endings), which affects the transmission of afferent signals. Simultaneously, the reduction of PGE2 in the hypothalamus allows for the resetting of the thermoregulatory set-point, which results in the activation of systemic heat-dissipation mechanisms.

Non-Prostaglandin Modulation and Matrix Influence

Beyond the primary COX mechanism, the active ingredient and its main metabolite engage secondary actions. These include the suppression of pro-inflammatory cytokines (like IL-1beta and TNF-alpha) and the modulation of Metalloproteinases, which are enzymes involved in cartilage matrix breakdown. This non-prostaglandin component involves the regulation of the inflammatory process at the cellular level and exerts an influence on cartilage matrix turnover.

Dosage and Administration Information

Official Administration of Acon (Aceclofenac)

Acon is supplied as a 100 mg film-coated oral tablet intended for systemic administration. The drug is taken by mouth, and the tablet should be swallowed whole with a sufficient quantity of liquid; it must not be crushed or chewed to ensure proper delivery. The official instruction is to administer the dose preferably with or after food.

Standard Dosing and Schedule

The standard total daily dosage for adults is 200 mg, which is administered as two separate 100 mg doses. This frequency pattern is typically maintained as one 100 mg tablet taken in the morning and the second 100 mg tablet taken in the evening. The overall use protocol requires employing the lowest effective dose for the shortest duration necessary, and the need for continued treatment must be re-evaluated periodically.

Population-Specific Dosing Rules

Official documents specify modifications for certain patient populations:

Hepatic Impairment: For patients with impaired liver function, the dose is generally reduced, with an initial daily dose suggested to be 100 mg (once daily).
Older Adults: While the pharmacokinetics of the medicine are not generally altered, making dose modification unnecessary, the lowest effective dose for the shortest duration is consistently advised.
Pediatric Use: The use of the medicine is not recommended in children due to a lack of sufficient clinical data from regulatory studies.
Missed Dose: If a dose is forgotten, the instruction is to omit the missed dose and take the next scheduled dose at the usual time; doubling the next dose to compensate is not instructed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acon

Research on Acon (Aceclofenac) has primarily focused on its use in research exploring symptoms related to chronic inflammatory joint diseases. The research approach usually involves Randomized Controlled Trials (RCTs), where patients are randomly assigned to receive either Acon, a placebo (an inactive substance), or another active treatment. These trials are used in research exploring how symptoms change over time. The findings from multiple RCTs are often gathered into Systematic Reviews or Meta-analyses to provide a broader view of the evidence landscape.

Evidence for Use in Osteoarthritis

Acon was studied for conditions characterized by fluctuating manifestations of joint pain and stiffness associated with Osteoarthritis (OA). Studies primarily included adults, often older adults. Researchers examined outcomes related to physical discomfort and daily functioning using tools like pain scores.

Findings describe patterns observed in the studies where measurements of pain and function were recorded as different during intermediate-term periods, typically 2 to 6 months. Evidence is limited on whether the medication influences underlying disease progression, as studies primarily explored symptomatic endpoints.

Evidence for Use in Rheumatoid Arthritis

Research examined Acon within studies exploring symptoms related to Rheumatoid Arthritis (RA). The studies often involved comparisons against other active treatments. Research monitored physical signs of inflammation, such as counts of tender and swollen joints, alongside patient-reported outcomes describing perceived discomfort.

Comparative trials documented different measurements of pain and swelling scores when comparing Acon and the comparator NSAID treatments. There is limited information for long-term outcomes that go beyond immediate symptom control, and the evidence base is less focused on establishing its distinct profile compared to the vast array of other existing NSAIDs.

Evidence for Acute Pain and Uncertainty

Research examined acute conditions associated with disruptive episodes, such as short-term low back pain (lumbago), in short-term RCTs. Research provides insight into short-term changes in pain scores that may be experienced. However, data for certain groups remain insufficient, such as for children and adolescents, and dedicated studies focused on patients with significant comorbidities are often not available.

For Acon, long-term effects are not fully established. Most clinical efficacy trials focused on intermediate-term periods, meaning evidence is limited concerning the durability of measured symptomatic changes over a very extended period.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Acon (FAQ)

Q: What happens if I forget to take Acon?

Official instructions state that if a dose is forgotten, it is instructed to be omitted, and the next scheduled dose is administered at the usual time. Taking a double dose to make up for the missed one is not instructed in the official product information.

Q: Can older adults use Acon safely?

Official guidance indicates that use in older adults is generally allowed but requires caution. This is because older adults have a documented increased risk of serious adverse reactions, especially involving the stomach and intestines. Official guidance indicates the lowest effective dose for the shortest duration is generally utilized.

Q: Is Acon safe for people who have kidney issues?

Acon is contraindicated (not recommended for use) in patients who have severe renal (kidney) failure. According to official eligibility documents, patients with mild to moderate kidney impairment may be treated under close medical surveillance.

Q: Does Acon interact with alcohol?

Official documents advise that close medical surveillance is noted as being necessary when a person who drinks alcohol regularly uses this drug. This cautionary note is based on a risk of potential stomach and intestinal bleeding.

Q: Does Acon affect blood pressure?

Official documents state that the medicine may reduce the efficacy of other heart and blood pressure drugs known as Antihypertensives. Acon and other drugs in its class have also been associated with reports of fluid retention and oedema in some patients.

Q: Is it normal to feel tired after taking Acon?

Official labeling reports side effects involving the nervous system, including dizziness and drowsiness. Tiredness or fatigue may be reported under these adverse reaction categories.

Q: What kind of monitoring is needed while taking Acon?

Patients with certain pre-existing conditions (e.g., impaired kidney, liver, or heart function) may be managed with close medical surveillance and monitoring of renal function. Furthermore, the need for continued treatment is often re-evaluated periodically to ensure the use duration is appropriate.

Q: Does Acon have a risk of overdose?

Regulatory information addresses overdose by noting that if excessive consumption is reported, supportive and symptomatic treatment is given to manage complications such as low blood pressure, gastrointestinal irritation, or convulsions.

Q: How is Acon eliminated from the body?

According to the official pharmacokinetics data, about two-thirds of a dose is excreted in the urine, primarily as breakdown products. The medicine's plasma-elimination half-life is approximately 4 hours.

Q: Is Acon the same type of medicine as [similar drug name]?

Acon is a prescription medicine whose active ingredient, Aceclofenac, belongs to the drug class known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). All medicines in this class share a similar primary function of reducing pain and inflammation.

Q: Can Acon cause a change in my sleep patterns?

Official product information reports side effects such as drowsiness, which is a nervous system effect. The labeling does not specifically report changes to general sleep patterns.

Q: Does Acon interact with common over-the-counter pain relievers?

Regulatory sources advise that the co-administration of Acon with other NSAIDs, including those that might be available over the counter, is avoided. This restriction is due to an increased risk of gastrointestinal adverse effects.

Q: Is Acon known to cause weight gain or loss?

Official product labeling for NSAIDs, including Acon, has been associated with reports of fluid retention and oedema (swelling caused by trapped fluid) in some patients. Fluid retention may potentially result in unusual weight changes.

Q: Is Acon addictive or habit-forming?

Acon is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not listed as a controlled substance by official regulatory bodies.

Q: Are there any specific foods I should avoid while using Acon?

Official instructions state that the medicine is typically administered preferably with or after food to help lessen the likelihood of side effects like stomach irritation. No specific food exclusions are listed in the regulatory documents.

Q: Do I need a prescription from a doctor to get Acon?

According to regulatory labeling, Acon is classified as a HUMAN PRESCRIPTION DRUG in its oral tablet formulation. This indicates that it requires a valid prescription for use.

Q: Are there any known long-term side effects of using Acon?

Regulatory information states that the risk of serious side effects, including serious Cardiovascular events (such as heart attack or stroke) and Gastrointestinal bleeding, may increase with the dose and duration of exposure.

Q: How long does Acon stay in your system after you stop taking it?

The medicine's plasma-elimination half-life is approximately 4 hours. This is the time required for the amount of drug in the body to be reduced by half.

Q: Is it okay to take Acon every day?

Official documents describe a standard total daily dosage, but regulatory guidance states that the need for continued treatment is often re-evaluated periodically. The use protocol requires employing the lowest effective dose for the shortest duration necessary.

Q: Can Acon be split or crushed?

Regulatory instructions mandate that the tablet should be swallowed whole with liquid. Official guidance states that the tablet is not designed to be crushed or chewed.

Q: What makes Acon different from other drugs for [condition]?

Acon's active ingredient is Aceclofenac, an NSAID that is chemically related to diclofenac. It is primarily recognized for its action as a preferential inhibitor of the COX-2 enzyme, which affects the body's inflammatory signaling.

Q: Are there any age restrictions for using Acon?

The medicine is not recommended for children and adolescents under 18 years of age because safety and effectiveness have not been clinically established in this group. Older adults generally require the lowest effective dose due to increased safety risks.

Q: Is it possible for Acon to stop working over time?

Research evidence indicates that most clinical efficacy trials focused on intermediate-term periods. This means that evidence is limited concerning the durability of measured symptomatic changes over a very extended period.

Q: Can Acon cause headaches?

Yes, regulatory product labeling reports headache as an adverse reaction under the Central Nervous System disorders category.

Q: Is Acon safe to use with heart medications?

Regulatory documents note that co-administration with certain heart medications, such as Antihypertensives or Cardiac Glycosides, may either reduce their efficacy or increase their plasma levels. The co-administration profile is detailed in the official interactions documents.

Q: Does Acon affect laboratory test results?

Official safety data includes hepatic (liver) enzymes increased as a common adverse reaction, which is a type of laboratory test change. The official guidance also advises the monitoring of renal (kidney) function for specific patient groups.

Q: Is Acon a stimulant or a sedative?

Acon is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its potential central nervous system effects are reported as drowsiness and dizziness, which are not characteristic of a stimulant.

How should Acon be stored and disposed of?

Acon (Aceclofenac oral tablets) must be stored and disposed of according to regulatory guidelines to ensure product integrity and environmental safety.

Storage Requirements

Acon must be kept at controlled room temperature, typically between 20 C and 25 C and must not exceed 30 C. The tablets must be protected from light and moisture and stored in their tightly closed original container.

Child Safety

It is mandatory to store Acon out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Acon must be disposed of in accordance with local pharmaceutical waste requirements. Due to the environmental toxicity of the active ingredient, the medicine must not be thrown into household trash or flushed down the toilet or drain.

Acon